buyWeak
Paul A. Wagner bought $15k of FBRX
See Remarks at Forte Biosciences, Inc.. 20,520 shares at an average of $0.71, traded Dec 13, 2023, filed Dec 15, 2023.
Conviction score
20Value
$15k
20,520 shares
Holdings after
1,813,236
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$15k at market
- 0Relative to holdingsHoldings up 1.1%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying4 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-058867, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 13, 2023 | POpen-market purchase Common Stock | +10,520 | $0.70 | $7,351 | 1,803,236 | Dec 15, 2023 |
| Dec 14, 2023 | POpen-market purchase Common Stock | +10,000 | $0.72 | $7,200 | 1,813,236 | Dec 15, 2023 |
Related signals
Other insiders at Forte Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | FBRXbuy Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | $255k 9,680 shares | +30% | |
| 42Moderate | FBRXbuy Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | $125k 22,514 shares | +273% | |
| 15Weak | FBRXbuy Forte Biosciences, Inc. | Paul A. Wagner See Remarks | $7,525 10,000 shares | +1% | |
| 20Weak | FBRXbuy Forte Biosciences, Inc. | Paul A. Wagner See Remarks | $19k 29,776 shares | +2% | |
| 25Weak | FBRXbuy Forte Biosciences, Inc. | Paul A. Wagner See Remarks | $30k 51,203 shares | +3% | |
| 10Weak | FBRXbuy Forte Biosciences, Inc. | Paul A. Wagner See Remarks | $3,220 7,366 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.